Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome

Summary

This phase Ib trial studies the side effects and best dose of ibrutinib when given together with azacitidine in treating patients with myelodysplastic syndrome that is likely to occur or spread (higher risk) and who were previously treated or untreated and unfit for or refused intense therapy. Ibrutinib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2016-05-17

Primary completion

2019-05-25

Completion

2019-11-07

Drugs

Indications